TORONTO, ONTARIO--(Marketwire - Nov 30, 2012) - Panacea Global, Inc. ("Panacea") (PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, announced today that Dr. Mahmood Moshiri, President and CEO of Panacea is scheduled to present its cancer detection technology and chair a session at BIT''s 3rd Annual World Congress of Biomarkers held December 2-4, 2012 in Guangzhou, China.
Dr. Moshiri will be delivering a keynote talk titled "HAAH, a Cancer Tumor Marker, as Companion Diagnostic Strategy". The venue is a part of BIT''s 2nd World Congress of MolMed, which consists of 4 concurrent congresses including the Congress of Biomarkers and will bring together international scientists and industry leaders to discuss the global growth and latest developments in biomarker discovery, leading new technologies and medical development.
Panacea''s CEO and its scientists will also take part in two other presentations during this congress, presenting Panacea''s cancer test that detects the presence of the human aspartyl (asparaginyl) β-hydroxylase (HAAH) in patients'' blood samples.
The second presentation entitled "Early diagnosis of cancer: HAAH-based serum immunoassay" describes Panacea''s prostate cancer (PC) detection test (PC Detect™) compared to the PSA test. The results of Panacea''s study concluded that HAAH aids in the identification of patients who are at greatest risk of PC, regardless of their PSA levels. Since many individuals with low PSA levels actually have prostate cancer and many individuals with elevated PSA levels do not, determination of serum HAAH is particularly useful.
The third presentation entitled "HAAH Levels as an indicator for patients at risk for lung cancer" describes Panacea''s lung cancer (LC) detection test (LC Detect™) demonstrating that HAAH is significantly elevated in the sera of all patients with NSCLC, the most common type of lung cancer. The HAAH test has both a high sensitivity and specificity for the detection of lung cancer. "The ability of the test to detect early stage disease suggests great utility in the screening of patients at high risk for NSCLC and other cancer types", commented Dr. Moshiri.
About HAAH Technology
Panacea''s early cancer detection test detects the presence of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells and detected in patients'' blood samples measured using an ELISA assay. In a double blind study of 857 samples, conducted previously by Panacea, the test showed 94.7% sensitivity, 94.3% specificity and an overall accuracy of 94.6%.
About Panacea Global
Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. The Company''s lead technology provides an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (PANG) is available at www.panaceaglobalinc.com.
Certain information contained in this document may include "forward-looking information". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management''s good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company''s control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.
- Disease & Medical Conditions
- prostate cancer
- lung cancer